Navigation Links
Oral COTI-2 is effective in a second animal model of human pancreatic cancer
Date:1/20/2010

London, Ontario (January 20, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

This most recent study was designed to determine first, the effectiveness of oral COTI-2 as a single agent, second, the effectiveness of COTI-2 in combination with Abraxane, a standard first line therapy for advanced pancreatic cancer, and third, the toxicity of chronically administered oral COTI-2 as a single agent and in combination with Abraxane in an animal model of human pancreatic cancer (PANC-1). The following results provide strong evidence for the continued development of COTI-2 in combination with conventional single agent therapy for the treatment of pancreatic cancer:

  • COTI-2 is effective as a single agent in an animal model of human pancreatic cancer.

  • COTI-2 plus Abraxane was significantly more effective than Abraxane as a single agent and this result was observed by day 28 of the study.

  • The combination treatment group receiving COTI-2 plus Abraxane responded earlier than the Abraxane alone.

  • Complete tumor regressions were observed more frequently in the combination treatment groups than with single agent Abraxane.

  • At the conclusion of the study mean tumor volumes in the Abraxane only treated animals were trending higher while mean tumor volumes in the combination treatment group were trending lower.

  • Chronic oral treatment with COTI-2 as a single agent or in combination with Abraxane was well tolerated with no treatment deaths or observable toxicity over the duration of the study.

"In 2010 pancreatic cancer remains the most lethal cancer and effective oral treatments with low toxicity are urgently needed. The results of this second set of experiments confirm that chronically administered oral COTI-2 is a well tolerated effective single agent and there is enhanced efficacy in combination with Abraxane in an animal model of human pancreatic cancer," said Dr. Wayne Danter, President and CSO of COTI. "These results extend previous findings for oral COTI-2 alone and in combination with gemcitabine in pancreatic cancer. We continue to add to the impressive data set for COTI-2, showing effectiveness and low toxicity, particularly in combination with first and second line agents, against multiple cancers."

COTI will present this new data to prospective partners at BioPartnering North America taking place January 24-26, 2010 in Vancouver, Canada. "We are once again delighted with these new experimental results providing further evidence supporting the commercial potential of oral COTI-2 in pancreatic cancer," said Mr. Michael Cloutier, CEO of COTI. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2."


'/>"/>

Contact: Michael Barr
mbarr@criticaloutcome.com
519-858-5157
Critical Outcome Technologies Inc
Source:Eurekalert

Related biology news :

1. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
2. Gamma globulin effective in treating eye infections caused by adenoviruses
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. Socioeconomic position associated with effectiveness of HIV drugs
5. New nanoparticle vaccine is more effective but less expensive
6. MIT model could improve some drugs effectiveness
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. New hope for horse lovers as effective control for killer ragwort is proposed
9. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
10. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
11. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... AUSTIN, Texas , Dec. 7, 2016 /PRNewswire/ ... development of revolutionary immunogene therapy treatments, today announced ... healthcare practice within a leading strategic communications and ... strategic communications program. The program will combine investor ... the objective of raising the profile of Genprex ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... recovery solutions for industrial facilities, today announced that one of the nation’s fastest ... use Cambrian’s novel water-energy purchase agreement (WEPA). Under the WEPA, a first for ...
(Date:12/7/2016)... Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew up hearing ... Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in the lines ... where the turtle became a minor sensation because no one could remember ever seeing one ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... on December 1, 2016 asking the Federal Drug Administration (FDA) to consider OA ... of OA, OARSI is concerned about the growing population of OA patients, many ...
Breaking Biology Technology: